Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Special Report

Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders

Daniel J. Drucker
CMAJ February 07, 2012 184 (2) E153-E154; DOI: https://doi.org/10.1503/cmaj.112127
Daniel J. Drucker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: d.drucker@utoronto.ca
  • Article
  • Responses
  • Metrics
  • PDF
Loading

See related articles by Kelsall at www.cmaj.ca/lookup/doi/10.1503/cmaj.112129, and by Koren and colleagues at www.cmaj.ca/lookup/doi/10.1503/cmaj.112128

Type 2 diabetes arises as a result of insufficient insulin production, commonly in the setting of impaired insulin action. Type 2 diabetes and obesity are major health problems that often affect the same patient. These conditions are increasing in prevalence and are associated with substantial health care costs, impaired quality of life, and considerable morbidity and mortality. The available treatments for these metabolic disorders have traditionally been complicated by incomplete efficacy, the need for frequent and expensive self-monitoring of blood glucose levels and associated adverse effects such as weight gain and hypoglycemia. Because the successful treatment of diabetes is directly associated with a decrease in its related complications, improvements in controlling blood glucose levels lead directly to enhanced quality of life for patients with diabetes.

I have studied how gastrointestinal hormones control the ingestion, absorption and disposal of nutrients for more than 25 years. In 1987, as a research fellow funded by the Medical Research Council, I described the action of a novel peptide hormone, glucagon-like peptide-1 (GLP-1), on insulin-producing islet cells.1 Glucagon-like peptide-1 directly stimulates the synthesis and secretion of insulin from islet cells. These findings yielded a new area for biologic investigation, namely the physiologic relevance and biologic activity of GLP-1 and related peptides. Since that discovery, my research has delineated how GLP-1 acts in the body to control the growth and survival of islet β cells, the regulation of food intake and body weight, and the function and survival of cardiovascular tissues.2–4 My work has shown how this hormone works in the immune system and in the control of postprandial lipid metabolism.5,6 The Drucker laboratory has generated novel mouse models lacking GLP-1 activity, permitting the delineation of the endogenous physiologic importance of the GLP-1 system in multiple tissues.7–9 My work also described the importance of the enzyme that degrades GLP-1, dipeptidyl peptidase-4 (DPP-4), showing that genetic elimination of DPP-4 produces healthy mice with improved insulin secretion and better glucose control.10

As a result of these studies and related investigations by other leading scientists, the pharmaceutical industry has developed two new classes of drugs to treat type 2 diabetes, which are based on the potentiation of GLP-1 activity.11 The first approved GLP-1 receptor agonist, exendin-4, was discovered by John Eng, and my team and I cloned the gene encoding the protein.12 The Drucker laboratory has published numerous papers showing the glucoregulatory and metabolic actions of GLP-1 in experimental models of diabetes. Because exendin-4 must be injected twice daily, and because a more recently approved agent, liraglutide, requires injection only once daily, I led the first Phase III trial of a once-weekly version of exendin-4. This drug, exenatide, has been approved for use in Europe, with approval in North America expected soon.13

A second class of drugs based on GLP-1 activity, the DPP-4 inhibitors, was approved in 2007. These drugs lower blood glucose levels by inhibiting the enzymatic breakdown of GLP-1, thereby prolonging its action. Multiple DPP-4 inhibitors, which can be taken once daily in tablet form, have been approved for the treatment of diabetes.

Improving the lives of people with diabetes

These two new classes of incretin-based therapy have improved the lives of people with diabetes for two principal reasons. First, as GLP-1 stimulates insulin and lowers blood glucose levels only when they are elevated, the risk of unpleasant hypoglycemic reactions associated with the use of these drugs is much lower than with most other antidiabetes agents. As a result, there is less need for self-monitoring blood glucose levels. Second, many classes of antidiabetes drugs (insulin, sulfonylureas and thiazolidinediones) cause weight gain. The DPP-4 inhibitors do not cause weight gain; in fact, taking GLP-1 receptor agonists, such as exenatide and liraglutide, often results in meaningful weight loss. The ability to lower blood glucose and simultaneously reduce body weight is a marked improvement in the options for treatment available to patients with type 2 diabetes.

The success and increasing popularity of these drugs have led to investigations into how these hormones, exemplified by GLP-1, exert their actions in various tissues. Multiple long-acting forms of GLP-1 are now being developed to treat diabetes and obesity, including several new preparations than can be administered once weekly, once monthly or semiannually. In addition, the first analogue of glucagon-like peptide-2, teduglutide,14 is expected to be approved for the treatment of short bowel syndrome in 2012.

The elucidation of the biology of these two peptides has exemplified the translational importance of basic science, and the GLP-1 receptor agonists and DPP-4 inhibitors have improved the health of millions of people with type 2 diabetes worldwide.

Key points
  • Therapies for type 2 diabetes have traditionally been characterized by incomplete efficacy, the need to self-monitor blood glucose levels, and associated adverse effects such as weight gain and hypoglycemia.

  • Dr. Drucker’s work on glucagon-like peptide-1 and dipeptidyl peptidase-4 has led to the development of several new classes of therapy for type 2 diabetes.

  • These new therapies have improved the lives of patients with diabetes by reducing the need for self-monitoring blood glucose levels and lowering the risk of hypoglycemia and weight gain.

  • The success of these agents has led to scientific investigations into how gut hormones exert their actions in various tissues, thereby exemplifying the translational importance of basic science.

Footnotes

  • The two highest-ranking winners of the 2011 CIHR/CMAJ competition for Top Achievements in Health Research are Daniel Drucker, and Gideon Koren and colleagues for the Motherisk team. Dr. Drucker describes his work on translational biology of glucagon-like peptides for metabolic and gastrointestinal disorders in the following essay. The essay by Dr. Koren and colleagues and synopses of the other four winning achievements are available at www.cmaj.ca.

  • Competing interests: Daniel Drucker is a consultant for Arisaph Pharmaceuticals, Diartis Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Merck Research Laboratories, Novo Nordisk, NPS Pharmaceuticals, Takeda and Transition Pharmaceuticals; he has received grants from GlaxoSmithKline, Merck and Novo Nordisk; he has received payment for lectures from Eli Lilly, Merck and Novo Nordisk; and he has patents pending and receives royalties for his work on dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-2 analogues. No other competing interests were declared.

References

  1. ↵
    1. Drucker DJ,
    2. Philippe J,
    3. Mojsov S,
    4. et al
    . Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434–8.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Drucker DJ
    . The biology of incretin hormones. Cell Metab 2006;3:153–65.
    OpenUrlCrossRefPubMed
    1. Li Y,
    2. Hansotia T,
    3. Yusta B,
    4. et al
    . Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278: 471–8.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Noyan-Ashraf MH,
    2. Momen MA,
    3. Ban K,
    4. et al
    . GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975–83.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Hadjiyanni I,
    2. Siminovitch KA,
    3. Danska JS,
    4. et al
    . Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 2010;53:730–40.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Hsieh J,
    2. Longuet C,
    3. Baker CL,
    4. et al
    . The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion. Diabetologia 2010;53:552–61.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Scrocchi LA,
    2. Brown TJ,
    3. MacLusky N,
    4. et al
    . Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 1996;2:1254–8.
    OpenUrlCrossRefPubMed
    1. Hansotia T,
    2. Baggio LL,
    3. Delmeire D,
    4. et al
    . Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004;53:1326–35.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Hansotia T,
    2. Maida A,
    3. Flock G,
    4. et al
    . Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007;117:143–52.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Marguet D,
    2. Baggio L,
    3. Kobayashi T,
    4. et al
    . Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 2000;97:6874–9.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Drucker DJ,
    2. Nauck MA
    . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–705.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Chen YE,
    2. Drucker DJ
    . Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272:4108–15.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Drucker DJ,
    2. Buse JB,
    3. Taylor K,
    4. et al
    . Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240–50.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Drucker DJ,
    2. Shi Q,
    3. Crivici A,
    4. et al
    . Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997;15:673–7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (2)
CMAJ
Vol. 184, Issue 2
7 Feb 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders
Daniel J. Drucker
CMAJ Feb 2012, 184 (2) E153-E154; DOI: 10.1503/cmaj.112127

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders
Daniel J. Drucker
CMAJ Feb 2012, 184 (2) E153-E154; DOI: 10.1503/cmaj.112127
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Improving the lives of people with diabetes
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Celebrating top achievements in health research 2012
  • Essay for the 2011 CIHR/CMAJ award: Motherisk — caring for mothers, protecting the unborn
Show more Special Report

Similar Articles

Collections

  • Topics
    • Diabetes

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire